Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease

Trial Profile

An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 06 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Pulmonary fibrosis; Pulmonary hypertension
  • Focus Therapeutic Use
  • Sponsors United Therapeutics Corporation
  • Most Recent Events

    • 08 Nov 2022 Status changed from completed to discontinued.
    • 19 Oct 2022 Results assessing the long term safety and tolerability of treprostinil in patients with PHA with interstitial lung disease, presented at the CHEST Annual Meeting 2022 by Annual Meeting of the American College of Chest Physicians.
    • 14 Oct 2022 According to a United Therapeutics Corporation media release, long-term data from this trial will be presented at the CHEST 2022 Annual Meeting hosted by the American College of Chest Physicians.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top